Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE)
2025-522403-17-00Phase 3Authorised
- Sponsor
- Almirall
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in discoid eczema comparing Ebglyss arm with Placebo arm (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Apr 2026; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
discoid eczema
Beyond the preview
Go deeper on 2025-522403-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522403-17-00.